This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Sultamicillin is a mutual prodrug of ampicillin and sulbactam useful in the treatment of infections caused by beta-lactamase-producing bacteria.
- Generic Name
- Sultamicillin
- DrugBank Accession Number
- DB12127
- Background
Sultamicillin has been used in trials studying the prevention and treatment of Ventilator Associated Pneumonia and Chronic Obstructive Pulmonary Disease (COPD).
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Sultamicillin (DB12127)
- Weight
- Average: 594.65
Monoisotopic: 594.14542091 - Chemical Formula
- C25H30N4O9S2
- Synonyms
- Sultamicilina
- Sultamicillin
- Sultamicillinum
- External IDs
- CP 49952
- CP-49,952
- CP-49952
- VD 1827
- VD-1827
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcemetacin Acemetacin may decrease the excretion rate of Sultamicillin which could result in a higher serum level. Acenocoumarol Sultamicillin may increase the anticoagulant activities of Acenocoumarol. Amikacin The serum concentration of Amikacin can be decreased when it is combined with Sultamicillin. Atracurium The therapeutic efficacy of Atracurium can be increased when used in combination with Sultamicillin. Atracurium besylate The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Sultamicillin. BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Sultamicillin. Capreomycin The serum concentration of Capreomycin can be decreased when it is combined with Sultamicillin. Cinoxacin The serum concentration of Cinoxacin can be increased when it is combined with Sultamicillin. Ciprofloxacin The serum concentration of Ciprofloxacin can be increased when it is combined with Sultamicillin. Cisatracurium The therapeutic efficacy of Cisatracurium can be increased when used in combination with Sultamicillin. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Sultamicillin hydrochloride SUI1Z5PXSN 76203-99-1 JLBADLWTHWGGNE-CGAOXQFVSA-N Sultamicillin tosilate 46940LU8EO 83105-70-8 FFCSPKNZHGIDQM-CGAOXQFVSA-N - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image SULTAMAT 250 MG 40 ML SUSPANSIYON Sultamicillin (250 mg/5ml) Suspension Oral ATABAY KİMYA SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey 
SULTAMAT 250 MG 70 ML SUSPANSIYON Sultamicillin (250 mg/5ml) Suspension Oral ATABAY KİMYA SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey
Categories
- ATC Codes
- J01CR50 — Combinations of penicillins
- J01CR — Combinations of penicillins, incl. beta-lactamase inhibitors
- J01C — BETA-LACTAM ANTIBACTERIALS, PENICILLINS
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as penicillins. These are organic compounds containing the penicillin core structure, which is structurally characterized by a penam ring bearing two methyl groups at position 2, and an amide group at position 6 [starting from the sulfur atom at position 1].
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Lactams
- Sub Class
- Beta lactams
- Direct Parent
- Penicillins
- Alternative Parents
- Alpha amino acid esters / N-acyl-alpha amino acids and derivatives / Alpha amino acid amides / Phenylacetamides / Acylals / Aralkylamines / Dicarboxylic acids and derivatives / Thiazolidines / Tertiary carboxylic acid amides / Sulfones show 11 more
- Substituents
- Acetal / Acylal / Alpha-amino acid amide / Alpha-amino acid ester / Alpha-amino acid or derivatives / Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle show 27 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- penicillanic acid ester (CHEBI:51770)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 65DT0ML581
- CAS number
- 76497-13-7
- InChI Key
- OPYGFNJSCUDTBT-PMLPCWDUSA-N
- InChI
- InChI=1S/C25H30N4O9S2/c1-24(2)17(29-20(32)16(21(29)39-24)27-19(31)15(26)12-8-6-5-7-9-12)22(33)37-11-38-23(34)18-25(3,4)40(35,36)14-10-13(30)28(14)18/h5-9,14-18,21H,10-11,26H2,1-4H3,(H,27,31)/t14-,15-,16-,17+,18+,21-/m1/s1
- IUPAC Name
- [(2S,5R,6R)-6-[(2R)-2-amino-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carbonyloxy]methyl (2S,5R)-3,3-dimethyl-4,4,7-trioxo-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
- SMILES
- [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(=O)OCOC(=O)[C@@H]1N2C(=O)C[C@@]2([H])S(=O)(=O)C1(C)C
References
- General References
- AIFA Product Information: Unasyn (sultamicillin) for oral use [Link]
- External Links
- PubChem Compound
- 444022
- PubChem Substance
- 347828426
- ChemSpider
- 392048
- ChEBI
- 51770
- ChEMBL
- CHEMBL506110
- ZINC
- ZINC000042834847
- Wikipedia
- Sultamicillin
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Chronic Obstructive Pulmonary Disease (COPD) 1 4 Withdrawn Prevention Ventilator Associated Bacterial Pneumonia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, film coated Oral Suspension Oral Powder, for solution Oral 20 g Powder, for suspension Oral Tablet, coated Oral Powder; suspension Oral Tablet Oral Powder, for suspension Oral 250 mg/5mL Injection Intramuscular; Intravenous 250 mg/5ml Powder, for suspension Oral 5 g Tablet, film coated Oral 750 mg Tablet Oral 375 mg Tablet Oral 750 mg Suspension Oral 5 g Tablet Oral 375 g Powder, for solution Oral 5 g Powder, for suspension Oral 250 MG Tablet, film coated Oral 375 mg Tablet, coated Oral 375 mg Tablet, coated Oral 750 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.283 mg/mL ALOGPS logP 1.55 ALOGPS logP -0.4 ChemAxon logS -3.3 ALOGPS pKa (Strongest Acidic) 11.71 ChemAxon pKa (Strongest Basic) 7.23 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 8 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 182.48 Å2 ChemAxon Rotatable Bond Count 9 ChemAxon Refractivity 138.12 m3·mol-1 ChemAxon Polarizability 58.76 Å3 ChemAxon Number of Rings 5 ChemAxon Bioavailability 1 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 21:24 / Updated at May 21, 2021 10:22